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correlation coefﬁcient of 0.51 for the change between day 0 and day 7 
(p=0.02) and of 0.59 for the change in the second week of RT (day 7 
and 14, p=0.02). This correlation was not observed for other cytokines. 
Moreover, IL-6 levels were higher in patients showing no metabolic 
response compared to responders: day 0 resp. 18.9 ± 7.6 and 6.0 ± 0.9 
(p=0.06), day 7 resp. 31.0 ± 13.0 and 9.5 ± 3.0 (p=0.03) and for day 14 
resp. 25.3 ± 12.2 and 8.5 ± 1.9 (p=0.10). Seventy days after RT, levels 
of IL-1b (r=-0.55, p=0.04) as well as neopterin (r=0.58, p=0.04) were 
positively correlated with clinically symptomatic pneumonitis (>grade 
1). Furthermore, the dyspnea score at this time point showed a graded 
correlation with plasma levels of neopterin (r=0.76, p<0.01) and the 
cough score with osteopontin levels (r=0.81, p<0.01), while these phe-
nomena were not observed during RT. 
Conclusions: Changes in SUVmax were positively correlated with 
changes in IL-6 levels during radiotherapy, suggesting that changes 
in FDG uptake might be partly explained by inﬂammation. Seventy 
days after radiotherapy, levels of neopterin were correlated with both 
symptomatic pneumonitis and dyspnea score, assuming cell-mediated 
immune activation in the development of pneumonitis. Furthermore, 
levels of osteopontin, a lungﬁbrosis related protein, were correlated 
with cough score after radiotherapy.
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Background: While standard chemotherapy for non-small cell lung 
cancer (NSCLC) confers a survival beneﬁt to patients and improves 
quality of life, a complete response to therapy is uncommon, especially 
for patients with advanced disease. Uncovering genomic signatures 
that predict drug response for speciﬁc tumors will allow for the rational 
selection of effective treatments for individual patients and lay the 
foundation for personalized treatment strategies.
Objective: To determine if genomic features present in pre-treatment 
tumor cells can predict response to chemotherapy and to identify novel 
genes associated with drug resistance.
Methods: A panel of archived pre-treatment lung tumor biopsies with 
recorded patient response to a standard doublet regime (cis-platinum/
vinorelbine) were selected and subdivided into “responders” and “non-
responders” based on clinical parameters. Following pathology review, 
tumor cells were isolated and DNA was extracted from formalin-ﬁxed, 
parafﬁn-embedded tissue sections. Molecular proﬁling of tumors was 
undertaken by whole genome tiling-set array comparative genomic hy-
bridization (aCGH). The SeeGH and SIGMA software programs were 
used for visual analysis of all aCGH proﬁles. A segmentation algorithm 
was applied to array data to identify DNA copy number alterations in 
each tumor. Statistical analysis of processed tumor genome data was 
used to deﬁne regions of signiﬁcant difference between the “responder” 
and “non-responder” subgroups.
Results: Comparative analysis of high resolution genome proﬁles for 
“responder” and “non-responder” tumors revealed segmental genomic 
gains and losses speciﬁc to each group. Genes within these regions 
of alteration are known to play a role in cellular processes that affect 
response to chemotherapeutic agents, including DNA repair and apop-
totic signalling. Functional experiments for candidate loci are ongoing.
Conclusions: High resolution analysis of pre-treatment tumor genomes 
reveals molecular signatures that can predict response to chemotherapy. 
Clinical application of such signatures will allow cancer treatments to 
be tailored to individual patients. In addition, candidate response genes 
within identiﬁed signatures may provide insight into drug resistance 
mechanisms and serve as novel therapeutic targets.
Funding for this work was provided by Genome Canada/Genome BC 
and Amgen, Inc.
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Background: Tobacco smoke is strongly correlated with lung carcino-
genesis, particularly for squamous cell carcinoma (SqCC). In addition 
to tobacco smoke, exposure to arsenical compounds in drinking water 
has also been strongly related to increased incidence of lung cancer, 
particularly SqCC.
In the northern part of Chile (Antofagasta City), the population has 
been chronically exposed to arsenic compounds in drinking water 
at high concentrations. Antofagasta shows the highest incidence 
(39.4/100,000 inhabitants) and mortality (33.3/100,000 inhabitants) 
rates for lung cancer in the country. Almost 70% of diagnosed cases are 
of the SqCC. However, the prevalence of smoking in Antofagasta is not 
greater relative to the rest of the country (approximately 20% smokers 
by population).
The purpose of this study is to compare DNA segment copy number 
changes in lung SqCC from patients with and without exposure to 
arsenic and or tobacco smoke to determine pathways that are unique to 
arsenic induced lung cancer. We also want to determine pathways that 
are common in the carcinogenesis process irrespective to the type of 
carcinogen exposure.
Methods: A panel of 13 parafﬁn-embedded lung SqCC was collected 
from the Hospital of Antofagasta on the basis of patient residence, more 
than 15 years living in the region prior to diagnosis, and no history of 
previous cancer. We divided this group in smokers (S-As group) and 
non-smokers (nonS-As) Twenty-one tumors from non-arsenic ex-
posed patients (S-noAs) were collected from British Columbia Cancer 
Agency (Canada) for comparison. Genomic proﬁling was performed 
by high resolution tiling path array comparative genomic hybridization 
(CGH). The SeeGH software was used for alignment and analysis of 
all array CGH proﬁles. Genomic regions with p-values less than 0.05 
(Fisher exact test) were used for analysis.
Results: Alterations in NS-As group are much lower than the other two 
groups. Overall, the frequency of alteration in 3q (the most consistently 
over-represented region in SqCC related to tobacco smoking) in nonS-
As group is lower than in smokers. We also found genomic regions 
with a high degree of similarity between S-noAs and NS-As e.g. losses 
at 6q16.1-3, 9q33.1-2 10q11.21 and gains at 12p12.3
NS-As group shows a statically signiﬁcantly higher frequency of 
copy number gains of a 4 Mb segment at 19p12. The same region is 
